Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Teva Acquires Generics Maker Taiyo
by Michael McCoy
May 23, 2011
| A version of this story appeared in
Volume 89, Issue 21
Israel’s Teva Pharmaceutical Industries has agreed to acquire 57% of Taiyo Pharmaceutical Industry for $460 million in cash. Teva is also extending an offer to buy the rest of Taiyo; the overall transaction values the Japanese firm at $1.3 billion. According to Teva, Taiyo is Japan’s third-largest generic drug company, with 2010 sales of $530 million. The additional sales will help Teva beat its goal of having $1 billion in annual Japanese sales by 2015. Japan, the world’s second-largest drug market, has a relatively low generics penetration of 23%, Teva notes.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X